Palvella Therapeutics’ (PVLA) “Buy” Rating Reiterated at HC Wainwright

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $38.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 141.73% from the company’s current price.

A number of other brokerages also recently commented on PVLA. Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They set an “overweight” rating for the company. TD Cowen started coverage on Palvella Therapeutics in a report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price objective on the stock.

Palvella Therapeutics Stock Up 1.1 %

Shares of Palvella Therapeutics stock opened at $15.72 on Tuesday. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $22.32. The company has a market capitalization of $176.38 million, a P/E ratio of -1.30 and a beta of 0.68.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, Director George M. Jenkins bought 4,000 shares of Palvella Therapeutics stock in a transaction dated Wednesday, December 18th. The stock was acquired at an average cost of $12.93 per share, with a total value of $51,720.00. Following the completion of the acquisition, the director now owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This represents a 2.26 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.39% of the stock is owned by company insiders.

Hedge Funds Weigh In On Palvella Therapeutics

A hedge fund recently bought a new stake in Palvella Therapeutics stock. BML Capital Management LLC purchased a new position in shares of Palvella Therapeutics (NASDAQ:PVLA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 42,130 shares of the company’s stock, valued at approximately $506,000. Palvella Therapeutics accounts for 0.3% of BML Capital Management LLC’s portfolio, making the stock its 18th biggest holding. BML Capital Management LLC owned 0.38% of Palvella Therapeutics at the end of the most recent quarter. 40.11% of the stock is owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.